mutations and sophisticated kar yotype. It follows a linear evolution in the CLL clone throughout the recurrent acquisition of CDKN2AGenetic susceptibility mechanisms. Most susceptibility loci map to non-coding locations in the genome, are mainly located in Lively promoters or enhancers, and modify the binding internet sites of numerous transcripti